Company profilePharmaceutical#578 of 1,318 in Pakistan✓ No DRAP alerts

Himmel Pharmaceuticals Private Limited DSL: 05-352-0065-016174D

Pharmaceutical company · 20 brands · 39 molecules

Ranked #9 of 44 companies in Antineoplastics

20 registered products 15 pharmaceutical brands 39 distinct molecules 0 DRAP alerts

Company overview

20
registered products
15
pharmaceutical brands
39
distinct molecules
5
therapeutic classes
0
DRAP alerts

Himmel Pharmaceuticals Private Limited DSL: 05-352-0065-016174D is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 20 product registrations across 39 distinct molecules. Its portfolio is concentrated in Antineoplastics and Immunosuppressants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Himmel

10 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

9
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20269

Top molecules by brand count

Bortezomib ...... 3.5 Mg2 brands
Paclitaxel ...... 100 Mg2 brands
Paclitaxel2 brands
Irinotecan 20Mg1 brand
Lenalidomide ...... 10 Mg1 brand
Lenalidomide ...... 25 Mg1 brand
Doxorubicin ...... 10 Mg1 brand
Doxorubicin ...... 50 Mg1 brand

Therapeutic classes

Antineoplastics · 9Immunosuppressants · 1Drugs For Treatment Of Bone Diseases · 1Antiemetics & Antinauseants · 1Antithrombotic Agents · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official27 products · Rs 690.93 – Rs 372,767.98
Median across source: Rs 17,473.5

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Pharmasol (Pvt) Ltd. holds 113 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant
Oncogen Pharma (Pvt) Limited holds 8 molecules not in this portfolio
CapecitabineDocetaxelDoxorubicinImatinibLenalidomideNilotinib
Himmel Pharmaceuticals Private Limited holds 32 molecules not in this portfolio
AfatinibAfatinib DimaleateAlbuminCaspofunginCisplatinCytarabine

Get the full profile for Himmel

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.